Coverage
-
July 14, 2014
Biotechnology Industry Organization and The Pharmaceutical Research and Manufacturers of America have told the Federal Circuit that its recent decision in a lawsuit over flu drug Tamiflu expanded the double-patent doctrine at a time that the doctrine is increasingly irrelevant because of changes in federal patent laws.
1 other articles on this case.
View all »